[
  {
    "ts": null,
    "headline": "How Analyst Views on Merck Are Evolving as Growth Prospects and Risks Shift",
    "summary": "Merck has seen its fair value estimate edge higher to $104.27, up from $102.33, following recent updates to its growth outlook. Analysts cite an improved revenue growth expectation and a small uptick in the discount rate as drivers for this modest price target increase. This reflects a balance of positive developments and evolving risks. Stay tuned to discover how you can monitor shifts in Merck's story as new information emerges. Analyst Price Targets don't always capture the full story...",
    "url": "https://finnhub.io/api/news?id=90d89e2ba51c31c01148b53db7ea54bb022f5c65c1b6bfc90ab8030a8f8b85af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764194773,
      "headline": "How Analyst Views on Merck Are Evolving as Growth Prospects and Risks Shift",
      "id": 137619116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck has seen its fair value estimate edge higher to $104.27, up from $102.33, following recent updates to its growth outlook. Analysts cite an improved revenue growth expectation and a small uptick in the discount rate as drivers for this modest price target increase. This reflects a balance of positive developments and evolving risks. Stay tuned to discover how you can monitor shifts in Merck's story as new information emerges. Analyst Price Targets don't always capture the full story...",
      "url": "https://finnhub.io/api/news?id=90d89e2ba51c31c01148b53db7ea54bb022f5c65c1b6bfc90ab8030a8f8b85af"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck (MRK) Is Up 9.6% After Pipeline Upgrade and Regulatory Wins and What's Next",
    "summary": "In the past week, Merck received a boost as Wells Fargo upgraded its rating, citing increased confidence in Merck’s drug pipeline and noting significant progress in regulatory approvals for new oncology and HIV treatments. A key insight is that analysts see Merck’s pipeline advancements and diversified business development as easing concerns about future revenue risks associated with Keytruda’s eventual loss of exclusivity. With fresh optimism about Merck’s product pipeline and recent...",
    "url": "https://finnhub.io/api/news?id=dd627053c1ade7d115505b9360ddaaae2645d7204aaf89aedc7be8bcfee3633c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764191283,
      "headline": "Why Merck (MRK) Is Up 9.6% After Pipeline Upgrade and Regulatory Wins and What's Next",
      "id": 137619117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In the past week, Merck received a boost as Wells Fargo upgraded its rating, citing increased confidence in Merck’s drug pipeline and noting significant progress in regulatory approvals for new oncology and HIV treatments. A key insight is that analysts see Merck’s pipeline advancements and diversified business development as easing concerns about future revenue risks associated with Keytruda’s eventual loss of exclusivity. With fresh optimism about Merck’s product pipeline and recent...",
      "url": "https://finnhub.io/api/news?id=dd627053c1ade7d115505b9360ddaaae2645d7204aaf89aedc7be8bcfee3633c"
    }
  },
  {
    "ts": null,
    "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
    "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
    "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764176336,
      "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
      "id": 137615519,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407294139/image_1407294139.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
      "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
    "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
    "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764174517,
      "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
      "id": 137615429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2009808479/image_2009808479.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
      "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b"
    }
  },
  {
    "ts": null,
    "headline": "Building A $100,000 Dividend Portfolio: Maximizing SCHD's Income With November's Top High-Yield Stocks",
    "summary": "This article presents a diversified $100,000 high-yield dividend portfolio for November 2025, blending income, dividend growth, and reduced volatility.",
    "url": "https://finnhub.io/api/news?id=c27cdc4703d413438a3c9bcaee7d662db3d1f54ef7388f325f8030c9c8e5042a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764169200,
      "headline": "Building A $100,000 Dividend Portfolio: Maximizing SCHD's Income With November's Top High-Yield Stocks",
      "id": 137615156,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/965085606/image_965085606.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "This article presents a diversified $100,000 high-yield dividend portfolio for November 2025, blending income, dividend growth, and reduced volatility.",
      "url": "https://finnhub.io/api/news?id=c27cdc4703d413438a3c9bcaee7d662db3d1f54ef7388f325f8030c9c8e5042a"
    }
  },
  {
    "ts": null,
    "headline": "Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?",
    "summary": "MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.",
    "url": "https://finnhub.io/api/news?id=57a8c648615118b4412dd208aa5f191aa984ef417b7aabbbf98c8c0f84e11a5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764168540,
      "headline": "Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?",
      "id": 137614525,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.",
      "url": "https://finnhub.io/api/news?id=57a8c648615118b4412dd208aa5f191aa984ef417b7aabbbf98c8c0f84e11a5a"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Stock: Is MRK Outperforming the Healthcare Sector?",
    "summary": "Merck has outperformed the healthcare sector over the past three months. Moreover, Wall Street analysts are moderately optimistic about its prospects.",
    "url": "https://finnhub.io/api/news?id=29bd2a5e46c9b048d4fcb82b03b907f529e609ab24c92086395b7b353914de5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764165675,
      "headline": "Merck & Co. Stock: Is MRK Outperforming the Healthcare Sector?",
      "id": 137614526,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck has outperformed the healthcare sector over the past three months. Moreover, Wall Street analysts are moderately optimistic about its prospects.",
      "url": "https://finnhub.io/api/news?id=29bd2a5e46c9b048d4fcb82b03b907f529e609ab24c92086395b7b353914de5f"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Participate in the Citi 2025 Global Healthcare Conference",
    "summary": "RAHWAY, N.J., November 26, 2025--Merck to Participate in the Citi 2025 Global Healthcare Conference",
    "url": "https://finnhub.io/api/news?id=407d5c2daf70009694a7399e2f0e981713603685cbb6321fe71c9574e4141f0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764159300,
      "headline": "Merck to Participate in the Citi 2025 Global Healthcare Conference",
      "id": 137611344,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 26, 2025--Merck to Participate in the Citi 2025 Global Healthcare Conference",
      "url": "https://finnhub.io/api/news?id=407d5c2daf70009694a7399e2f0e981713603685cbb6321fe71c9574e4141f0b"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference",
    "summary": "RAHWAY, N.J., November 26, 2025--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference",
    "url": "https://finnhub.io/api/news?id=e82adeb127be0cc2722ea344e9d82c31dff53ffcf1686ec631f4c926d654e291",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764157500,
      "headline": "Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference",
      "id": 137611345,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 26, 2025--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference",
      "url": "https://finnhub.io/api/news?id=e82adeb127be0cc2722ea344e9d82c31dff53ffcf1686ec631f4c926d654e291"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Wednesday: Dell, HP, Workday, Deere",
    "summary": "↗️ Dell (DELL): The computer and software maker raised full-year guidance and forecast AI server shipments would more than double. Shares rose nearly 5% premarket. ↘️ HP (HPQ): The computer and printer maker plans to cut up to 10% of its workforce as it invests further in artificial intelligence.",
    "url": "https://finnhub.io/api/news?id=f1b3822132d791fb62e8d5987e3d7c60a60d09065a21d7b5949be7f2cc86c81b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764157395,
      "headline": "Stocks to Watch Wednesday: Dell, HP, Workday, Deere",
      "id": 137611346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "↗️ Dell (DELL): The computer and software maker raised full-year guidance and forecast AI server shipments would more than double. Shares rose nearly 5% premarket. ↘️ HP (HPQ): The computer and printer maker plans to cut up to 10% of its workforce as it invests further in artificial intelligence.",
      "url": "https://finnhub.io/api/news?id=f1b3822132d791fb62e8d5987e3d7c60a60d09065a21d7b5949be7f2cc86c81b"
    }
  },
  {
    "ts": null,
    "headline": "Hedge Funds Pile Into Health Stocks Leading Market in Rotation",
    "summary": "The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks.  Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation.  Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.",
    "url": "https://finnhub.io/api/news?id=3768daf75b4e70ec346d2eb5b0e4f04e7f887660fac02bb04248c747f2d50a79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764153000,
      "headline": "Hedge Funds Pile Into Health Stocks Leading Market in Rotation",
      "id": 137611229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks.  Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation.  Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.",
      "url": "https://finnhub.io/api/news?id=3768daf75b4e70ec346d2eb5b0e4f04e7f887660fac02bb04248c747f2d50a79"
    }
  },
  {
    "ts": null,
    "headline": "Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices",
    "summary": "The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,",
    "url": "https://finnhub.io/api/news?id=ed453e3d99118aaec5caa763ba61f4f17ea380d03972a2844140b4163ff336ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764151222,
      "headline": "Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices",
      "id": 137611270,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,",
      "url": "https://finnhub.io/api/news?id=ed453e3d99118aaec5caa763ba61f4f17ea380d03972a2844140b4163ff336ee"
    }
  },
  {
    "ts": null,
    "headline": "BofA Raises Merck (MRK) Price Target to $105, Keeps Buy Rating",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Stocks to Buy for Medium Term. On November 17, BofA analyst Tim Anderson raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) to $105 from $98 and maintained a Bu⁠y ratin​g on the share‍s, as reported by The Fly. He‌ de​scribed the Cidara […]",
    "url": "https://finnhub.io/api/news?id=1040ac7c936483841b257dbb8c6ad76f0ff4f4a1a9ae91580d9c0810a5345e90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764134663,
      "headline": "BofA Raises Merck (MRK) Price Target to $105, Keeps Buy Rating",
      "id": 137611349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Stocks to Buy for Medium Term. On November 17, BofA analyst Tim Anderson raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) to $105 from $98 and maintained a Bu⁠y ratin​g on the share‍s, as reported by The Fly. He‌ de​scribed the Cidara […]",
      "url": "https://finnhub.io/api/news?id=1040ac7c936483841b257dbb8c6ad76f0ff4f4a1a9ae91580d9c0810a5345e90"
    }
  },
  {
    "ts": null,
    "headline": "Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks",
    "summary": "Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.",
    "url": "https://finnhub.io/api/news?id=eeff6129ad885e3d224956bac281d5146884c2e07f2977badfd24d7a5d9c41e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764127935,
      "headline": "Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks",
      "id": 137611350,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.",
      "url": "https://finnhub.io/api/news?id=eeff6129ad885e3d224956bac281d5146884c2e07f2977badfd24d7a5d9c41e4"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Buy Now for Big Payout Growth Ahead",
    "summary": "Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.",
    "url": "https://finnhub.io/api/news?id=6f5314fcb91a309d4177a633024243ea2d3793e5b290c51d3bc95697d9833e91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764117002,
      "headline": "2 Dividend Stocks to Buy Now for Big Payout Growth Ahead",
      "id": 137611351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.",
      "url": "https://finnhub.io/api/news?id=6f5314fcb91a309d4177a633024243ea2d3793e5b290c51d3bc95697d9833e91"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Negotiates Lower Prices for Ozempic and 14 Other Drugs",
    "summary": "The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening an effort to rein in drug costs.  The new prices, which will take effect in 2027, shave 38% to 85% off the list prices for drugs for diseases including asthma, cancer and diabetes.  The reductions are estimated to save Medicare, the health-insurance program for the elderly, $12 billion.",
    "url": "https://finnhub.io/api/news?id=1c30417e270008628fa06e7b14fa125df9b5828a9df713babb9b2f8a3c4b1378",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764116520,
      "headline": "U.S. Negotiates Lower Prices for Ozempic and 14 Other Drugs",
      "id": 137611352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening an effort to rein in drug costs.  The new prices, which will take effect in 2027, shave 38% to 85% off the list prices for drugs for diseases including asthma, cancer and diabetes.  The reductions are estimated to save Medicare, the health-insurance program for the elderly, $12 billion.",
      "url": "https://finnhub.io/api/news?id=1c30417e270008628fa06e7b14fa125df9b5828a9df713babb9b2f8a3c4b1378"
    }
  }
]